Population-Based Multicentric Survey of Hepatitis B Infection and Risk Factors in the North, South, and Southeast Regions of Brazil, 10–20 Years after the Beginning of Vaccination

Ricardo A. A. Ximenes, Gerusa M. Figueiredo, Maria Regina A. Cardoso, Airton T. Stein, Regina C. Moreira, Gabriela Coral, Deborah Crespo, Alex A. dos Santos, Ulisses R. Montarroyos, Maria Cynthia Braga, and Leila M. M. B. Pereira for the Hepatitis Study Group

Hospital Universitário Oswaldo Cruz, Faculdade de Ciências Médicas de Pernambuco, Universidade de Pernambuco, Pernambuco, Brazil; Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Cidade Universitária, Pernambuco, Brazil; Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil; Departamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo, São Paulo, Brazil; Fundação Universidade Federal de Ciências da Saúde do Porto Alegre, Rio Grande do Sul, Brazil; Instituto Adolfo Lutz, São Paulo, Brazil; Secretaria de Saúde Pública do Estado do Pará, Pará, Brazil; Instituto Bioestatístico, Pará, Brazil; Instituto de Ciências Biológicas, Universidade de Pernambuco, Pernambuco, Brazil; Fundação Oswaldo Cruz, Centro de Pesquisas Aggeu Magalhães, Cidade Universitária, Pernambuco, Brazil; Instituto do Fígado de Pernambuco, Pernambuco, Brazil

Abstract. A population-based hepatitis survey was carried out to estimate the prevalence of hepatitis B virus (HBV) infection and its predictive factors for the state capitals from the north, south, and southeast regions of Brazil. A multistage cluster sampling was used to select, successively, census tracts, blocks, households, and residents in the age group 10–69 years in each state capital. The prevalence of hepatitis B surface antigen (HBsAg) was lower than 1% in the north, southeast, and south regions. Socioeconomic condition was associated with HBV infection in north and south regions. Variables related to the blood route transmission were associated with HBV infection only in the south whereas those related to sexual behavior were associated with HBV infection in the north and south regions. Drug use was associated in all regions, but the type of drug differed. The findings presented herein highlight the diversity of the potential transmission routes for hepatitis B transmission in Brazil. In one hand, it reinforces the importance of national control strategies of large impact already in course (immunization of infants, adolescents, and adults up to 49 years of age and blood supply screening). On the other hand, it shows that there is still room for further control measures targeted to different groups within each region.

INTRODUCTION

Hepatitis B virus (HBV) infection is still a major public health problem worldwide. Around 90% of infants infected perinatally become chronic carriers, unless vaccinated at birth. Approximately 25% of persons who became chronically infected during childhood and 15% of persons chronically infected after childhood die of cirrhosis or liver cancer.

In 1989, the Brazilian government implemented HBV immunization for infants in the western area of the Amazonas State because of the high prevalence, and gradually expanded the program to the other northern states. In 1993, states in south and southeast regions extended immunization up to the age of 4 years. In 1998, the HBV vaccine was incorporated into the immunization schedule for infants as a national policy. Subsequently, children and adolescents (2001), young adults up to 29 years (2011) of age, and adults up to 49 years (2013) of age were included. Vaccination of risk groups started in 1992, and new groups were successively added to the original list.

A population-based survey conducted in 27 Brazilian cities among 17,749 children aged 18–30 months in 2007 estimated that 86.7% completed the three-dose series by 12 months of age. Most of the Brazilian territory has been classified as having intermediate and low endemicity for HBV infection, the exception being the high-HBV endemicity area located in the western Amazon region and restricted areas of some states in the south and southeast regions.

A national population-based hepatitis survey was thus conducted aiming at estimating the prevalence of HBV infection and its predictive factors after about 10–20 years of the beginning of vaccination. Here we report the results for all the state capitals from the north, south, and southeast regions. Results showing low prevalence in the northeast and central-west regions and in the Federal District of Brasília have already been published.

MATERIALS AND METHODS

Study populations and study samples. The Brazilian National Hepatitis A, B, and C Survey is a cross-sectional household study in a representative sample of the population resident in all the state capitals and in the federal district.

We report on the hepatitis B survey conducted in the southeast (four capital cities), south (three capital cities), and north (seven capital cities) regions, during March 2007–January 2008 (Figure 1). The target population (10–69 years of age) comprised 14.9 million inhabitants in the southeast region, 2.6 million in the south, and 2.9 million in the north region.

More detailed information on sampling and data collection has already been reported. In brief, the study population was stratified into two age strata (10–19 and 20–69 years) and by state capital in each region; the samples for each age group were allocated among the state capitals using a constant sampling fraction. A random sample was obtained using a multistage cluster sampling strategy based on census tract, which is the smallest geographic unit with sociodemographic data available (approximately 300 households corresponding to 1,000 inhabitants). To improve sampling efficiency, the census tracts were, when necessary, either broken up or grouped together according to preestablished criteria to make the primary
sampling unit (PSU). The PSUs were then ordered according to the number of years of schooling of the head of household, and a systematic sample was taken from this ordered list of PSUs, with probability proportional to size, so that all socioeconomic groups would be represented. In the second stage, blocks were systematically selected with probability proportional to size within each PSU and, finally, a systematic sampling of households was drawn in each block. All residents in the age group considered were recruited in the selected households. Number of years of schooling of the head of household was selected to order the census tracts because it is strongly correlated with income.

A total of 10,184 individuals were enrolled in the study: 3,689 persons in 1,842 households living in 154 census tracts in the southeast region; 4,189 persons in 2,047 households located in 91 census tracts in the south region; and 2,306 persons in 1,084 households living in 213 census tracts in the north region.

Data collection. Data on socioeconomic status and potential risk factors were collected by trained interviewers using a structured questionnaire during household visits. Self-reported HBV vaccine status was assessed and confirmed by the vaccination card, when available.

Laboratory tests and definitions. Blood samples were collected after the interview and tested for antibodies against hepatitis B core antigen (HBc) using an enzyme-linked immunosorbent assay (AxsymTM; Abbott Laboratories, Abbott Park, IL) in central public health laboratories. Positive samples were tested for antibodies against hepatitis B surface antigen (HBs); samples negative for antibodies against hepatitis B surface antigen (anti-HBs) were tested for hepatitis B surface antigen (HBsAg), using the same technique (AxsymTM). Borderline results were retested and indeterminate results were excluded from the analysis.

Chronic HBV infection was determined as the presence of HBsAg and anti-HBc. The presence of HBV infection, past or present, was determined by detection of anti-HBc, in accordance with the National Health and Nutritional Examination Survey.8

Statistical analysis. Prevalence and 95% confidence intervals (95% CI) were corrected by the design effect. Risk factors comprised questions on drug use and sexual practice, and therefore the analysis included only persons aged 13–69 years. Association between HBV infection and individual variables, adjusted by age, was assessed by odds ratio (OR) with a 95% CI. Variables associated in bivariate analyses with \( P < 0.20 \) were successively included in a multivariate logistic regression model. ORs were corrected using the random design effect caused by the study design and weighting caused by the difference in sampling fractions between age groups.

For participants who presented a vaccination card, the predictive positive and negative values of the self-reported HBV vaccination status were estimated.

Stata, version 9.2 (College Station, TX), was used for statistical analysis.

Sample size. Details on sample size and sampling procedures have already been published.7

Ethical issues. Interviews and blood sample collection were performed after a written informed consent was signed. For minors, the legal guardian consent was obtained. The project was approved by the National Research Ethics Committee of the Brazilian National Health Council and by the local research ethics committees.
Prevalence of hepatitis B antibodies, percentage of individuals vaccinated for hepatitis B, and estimated population ever infected in a representative sample of individuals living in the state capitals of Brazil, 2005–2009

| Setting age (years) group | Participants | Prevalence* % (95% CI) | Vaccination status (%) | State capitals population | Estimated persons ever infected n (95% CI) |
|--------------------------|--------------|------------------------|------------------------|---------------------------|------------------------------------------|
| North                    |              |                        |                        |                           |                                          |
| 10–19                    | 1,157        | 1.1 (0.9–1.4)          | 68.9                   | 860,922                   | 9,471 (7,749–12,053)                     |
| 20–69                    | 1,149        | 11.6 (10.7–12.4)       | 49.8                   | 2,093,269                 | 242,820 (223,980–259,356)                |
| Southeast                |              |                        |                        |                           |                                          |
| 10–19                    | 1,794        | 0.61 (0.27–0.95)       | 67.4                   | 3,295,110                 | 20,100 (8,897–31,304)                    |
| 20–69                    | 1,867        | 7.90 (6.60–9.19)       | 23.2                   | 11,661,984                | 921,297 (769,691–1,071,737)              |
| South                    |              |                        |                        |                           |                                          |
| 10–19                    | 1,801        | 1.58 (0.83–2.32)       | 76.2                   | 586,270                   | 9,264 (4,867–13,602)                     |
| 20–69                    | 2,373        | 11.3 (9.94–12.7)       | 24.0                   | 2,043,761                 | 230,944 (203,150–259,558)                |

CI = confidence interval. *Prevalence adjusted for random effect.

Each positive result was delivered by the medical coordinator, and all negative results were sent by mail to participants. Individuals who were positive for HBsAg were referred to hepatology or infectology outpatient clinics in public referral hospitals for clinical evaluation. Persons negative for HBV were referred to public health services for vaccination.

RESULTS

Prevalence. The prevalence of anti-HBe stratified according to region and age group is shown in Table 1. The prevalence in the age group 10–19 years was higher in the south whereas that in the age group 20–69 years was higher in the north.

A total of 15, 14, and 21 carriers were identified in the north, southeast, and south, respectively.

Vaccination status was reported by approximately 78% of the population in all regions. Of the 3,338 participants who presented a vaccination card, the predictive positive and negative values of the self-reported HBV vaccination status were 90.38% (95% CI: 87.03–93.10%) and 75.47% (95% CI: 61.72–86.24%) for the north, 95.97% (95% CI: 94.50–97.13%) and 96.21% (95% CI: 91.38–98.76%) for the south, and 95.67% (95% CI: 94.11–96.92%) and 89.45% (95% CI: 84.59–93.19%) for the southeast region. Approximately 45.6% reported HBV vaccination. Residents of the north region reported higher frequencies of HBV vaccination (56%) compared with those in the south (41%) and southeast (40%) regions. Vaccination status for persons aged ≥ 20 years was significantly higher in the north compared with the south and southeast regions (Table 1).

Bivariate analysis. Tables 2–5 show the association of individual risk factors with HBV infection, adjusted by age. For sexual behavioral factors, in the bivariate analysis, the reference category was that with lower potential of transmission (among those who had initiated sexual life), whereas in the multivariate, the

| Table 2
| Individual factors | North | OR (95% CI)* | P value | South | OR (95% CI)* | P value |
|-------------------|-------|--------------|---------|-------|--------------|---------|
| Sex               |       |              |         |       |              |         |
| Female            | 1,094 | 1.0          | –       | 1,739 | 1.0          | –       |
| Male              | 875   | 1.39 (1.01–1.91) | 0.041  | 1,368 | 1.60 (1.13–2.26) | 0.007 |
| Literacy          |       |              |         |       |              |         |
| Yes               | 1,909 | 1.0          | –       | 3,009 | 1.0          | –       |
| No                | 56    | 2.93 (1.47–5.84) | 0.002  | 98    | 0.67 (0.31–1.42) | 0.303 |
| Schooling         |       |              |         |       |              |         |
| Illiterate        | 112   | 1.0          | –       | 190   | 1.0          | –       |
| Basic level       | 797   | 0.61 (0.37–0.99) | 0.047  | 1,389 | 1.06 (0.62–1.79) | 0.823 |
| Secondary level   | 814   | 0.59 (0.32–1.05) | 0.075  | 1,172 | 0.84 (0.45–1.54) | 0.578 |
| University        | 217   | 0.34 (0.16–0.71) | 0.004  | 334   | 0.47 (0.21–1.07) | 0.074 |
| Paid work past week |       |              |         |       |              |         |
| Yes               | 813   | 1.0          | –       | 1,420 | 1.0          | –       |
| No                | 1,156 | 0.54 (0.40–0.73) | 0.000  | 1,687 | 0.86 (0.60–1.23) | 0.420 |
| Hospitalization   |       |              |         |       |              |         |
| Never             | 1,203 | 1.0          | –       | 2,216 | 1.0          | –       |
| Past 12 months    | 182   | 0.77 (0.42–1.40) | 0.388  | 168   | 1.02 (0.47–2.20) | 0.948 |
| Ever              | 559   | 1.04 (0.69–1.56) | 0.847  | 718   | 1.07 (0.70–1.64) | 0.726 |
| Blood transfusion |       |              |         |       |              |         |
| Never             | 1,815 | 1.0          | –       | 2,894 | 1.0          | –       |
| Past 12 months    | 44    | 1.45 (0.50–4.20) | 0.494  | 40    | 1.41 (0.51–3.92) | 0.505 |
| Ever              | 62    | 1.65 (0.82–3.32) | 0.157  | 136   | 1.45 (0.72–2.94) | 0.294 |
| Surgery           |       |              |         |       |              |         |
| Never             | 1,177 | 1.0          | –       | 1,725 | 1.0          | –       |
| Past 12 months    | 180   | 0.98 (0.58–1.65) | 0.946  | 270   | 1.39 (0.82–2.34) | 0.211 |
| Ever              | 591   | 0.71 (0.49–1.02) | 0.066  | 1,109 | 1.24 (0.80–1.92) | 0.322 |

CI = confidence interval. OR = odds ratio. *Weighted ORs adjusted for random effect and age.
Relative odds of hepatitis B infection for individual factors among persons 13–69 years of age in three regions in Brazil, 2005–2009

| Individual factors                  | North               | South               | P value |
|-------------------------------------|---------------------|---------------------|---------|
|                                     | OR (95% CI)*        | OR (95% CI)*        |         |
| Endoscopy                           |                     |                     |         |
| Never                               | 1.714 (1.0–2.906)   | 2.595 (1.0–2.906)   |         |
| Past 12 months                      | 1.0                 | 1.0                 |         |
| Ever                                | 1.26 (0.91–1.709)   | 1.709 (1.0–2.75)    |         |
| Dental treatment                    |                     |                     |         |
| Never                               | 1.84 (1.0–3.67)     | 3.06 (1.0–9.43)     |         |
| Past 12 months                      | 0.96 (0.54–1.68)    | 1.458 (0.98–2.14)   |         |
| Ever                                | 0.95 (0.48–1.85)    | 1.458 (0.98–2.14)   |         |
| Health-care-related job             |                     |                     |         |
| No                                  | 1.823 (1.0–3.302)   | 2.868 (1.0–3.302)   |         |
| Yes                                 | 1.37 (0.77–2.386)   | 1.39 (0.62–2.43)    |         |
| Tattoo                              |                     |                     |         |
| No                                  | 1.780 (1.0–3.185)   | 2.773 (1.0–3.185)   |         |
| Yes                                 | 0.98 (0.44–2.13)    | 3.34 (1.84–5.37)    |         |
| Body piercing                       |                     |                     |         |
| No                                  | 1.787 (1.0–3.122)   | 2.700 (1.0–3.122)   |         |
| Yes                                 | 0.93 (0.43–1.98)    | 4.07 (0.41–6.15)    |         |
| Share toothbrush                    |                     |                     |         |
| No                                  | 1.705 (1.0–3.424)   | 2.900 (1.0–3.424)   |         |
| Yes                                 | 0.51 (0.26–0.99)    | 2.07 (0.93–4.21)    |         |
| Sharing of cutting objects          |                     |                     |         |
| No                                  | 0.616 (1.0–1.370)   | 1.010 (1.0–1.370)   |         |
| Yes                                 | 0.87 (0.62–1.22)    | 2.097 (1.30–1.90)   |         |

CI = confidence interval; OR = odds ratio.

*Weighted ORs adjusted for random effect and age.

Another sexual partner besides current partner

Initiated sexual life

No: 467 (1.0–1.036)
Yes: 910 (1.0–1.581)

Previous STD

No: 1,301 (1.0–2.574)
Yes: 155 (1.0–2.574)

Current partner had hepatitis

No: 1,208 (1.0–2.306)
Yes: 59 (1.0–2.306)

Previous sexual relationship with known HBV carrier

No: 1,317 (1.0–2.664)
Yes: 76 (1.0–2.664)

Multivariable analysis. The multivariate model showed that age was an independent risk factor in all regions (Table 6). Socioeconomic condition was associated with HBV infection in north and south regions. Variables related to the blood route transmission were associated with HBV infection only in the south whereas those related to sexual behavior were associated

| Sexual behavioral factors                      | North               | South               | P value |
|------------------------------------------------|---------------------|---------------------|---------|
| Relative odds of hepatitis B infection for sexual behavioral factors among persons 13–69 years of age in three regions in Brazil, 2005–2009

Initiated sexual life

No: 583 (1.0–744)
Yes: 1,475 (1.0–2,871)

Condom use

Yes, regularly: 495 (1.0–792)
Yes, sometimes: 289 (0.93–432)

Bisexual

No: 1,226 (1.0–2,639)
Yes: 52 (1.0–61)

Another sexual partner besides current partner

No: 227 (1.0–41)
Yes: 910 (1.0–1,581)

Previous STD

No: 2,574 (1.0–2,574)
Yes: 291 (1.0–2,574)

Current partner had hepatitis

No: 2,306 (1.0–2,306)
Yes: 125 (1.0–2,306)

Previous sexual relationship with known HBV carrier

No: 2,664 (1.0–2,664)
Yes: 76 (1.0–2,664)

CI = confidence interval; HBV = hepatitis B virus; STD = sexually transmitted disease; OR = odds ratio.

*Weighted ORs adjusted for random effect and age.
in the north and south regions. Drug use was associated in all regions, but the type of drug differed. The south was the region with a wider spectrum of risk factors.

**DISCUSSION**

Knowledge of region- and age-specific prevalence of hepatitis B infection is important for evaluating vaccination programs and national disease prevention and control efforts. Our findings classify these regions as having low HBV endemicity, rather than the intermediate and high endemicity defined by previous studies in the last century and past decade. Nevertheless, the overall estimation of individuals chronically infected with HBV was 18,612, 43,367, and 12,624 in the north, southeast, and south, respectively.

The introduction of vaccination in these regions happened in different years and in different age groups. In the data collection period, vaccinated cohorts might have reached the age of 20 years. Note that in the north, area that was considered as having high prevalence, the vaccination status for participants over 20 years of age was significantly higher compared with the south and southeast regions.

Countries with high prevalence of HVB infection that began universal immunization have shown decreased prevalence, as occurred in Taiwan, China, and Saudi Arabia. A reduction was also observed in low-endemicity countries, such as the United States and Canada.

In Brazil, a population-based study in the western Amazon State, in a region called Labrea (where the association of hepatitis B and D virus infection was first identified), revealed a significant reduction in the HBsAg rate in the community, 11 years after the introduction of the HBV vaccination program, categorizing the area as intermediate endemicity (formerly classified as high).

Our data revealed a prevalence of HBsAg similar to the data for all capitals of the northeast, central-west regions, and in the federal capital.

Although population-based data for HBV infection before and after vaccination are not available for large areas, the low-endemicity level found strongly suggest an impact of the vaccination policy. The Brazilian National Immunization Program attained high vaccination coverage and sustainability as vaccines were freely supplied by the National Self-Sufficiency Program in Immunobiologicals.

Recent publication with the objective of estimating age-, sex-, and region-specific prevalence of chronic HBV infection in the world and calculate the absolute number of persons chronically infected, using an empirical Bayesian hierarchical model, showed that from 1990 to 2005 the prevalence of chronic HBV infection decreased in most regions. Brazil was categorized as a region of low endemicity.

The results of this survey indicate different patterns of HBV transmission in the areas studied. The factors independently associated with HBV infection in the north region were mainly related to the sexual route and to the use of drugs; in the southeast to the use of drugs; while in the south to the sexual route, use of drugs and also to the blood route. An inverse relationship with socioeconomic conditions (schooling) was found in the north and south regions. Use of drugs that were not related to the mechanism of transmission of HBV was also associated with seropositivity.

Age was an independent predictor for HBV infection, as reported in the literature, indicating length of time for viral exposures and initiation of sexual activity. The increasing vaccine coverage of younger age groups may also have contributed to the difference in prevalence between the two age groups considered (10–19 and 20–69 years). Our study found higher risk of HBV infection in men only in the southeast region, like in the United States and in Brazilian studies with individuals recruited from restricted areas, volunteers, or outpatient clinics.

The sexual behavior associated with exposure to HBV was not the same in the different regions. In the north, there was a greater chance of HBV infection for those whose partner had sex with individuals of the same sex, similar to what was found in the northeast. Male–male sexual activity and having a homosexual partner have been reported as risk factors for HBV infection in other studies. Individuals whose partners

---

**Table 5**

| Drug use-related factors | North          |                      | South        |                      | North          |                      | South        |                      |
|-------------------------|----------------|----------------------|--------------|----------------------|----------------|----------------------|--------------|----------------------|
|                         | No. | OR (95% CI)* | P value | No. | OR (95% CI)* | P value | No. | OR (95% CI)* | P value |
| Ever used smoked drugs  | No. | 1,651 | 1.0 | – | 2,814 | 1.0 | – | 3,038 | 1.0 | – |
|                         | Yes | 191  | 1.73 (1.19–2.55) | 0.005 | 290  | 1.72 (1.08–2.73) | 0.022 | 570  | 1.31 (0.87–1.97) | 0.187 |
| Ever used inhaled drugs | No  | 1,902 | 1.0 | – | 3,068 | 1.0 | – | 3,512 | 1.0 | – |
|                         | Yes | 35   | 1.67 (0.75–3.67) | 0.204 | 31   | 4.98 (1.60–15.5) | 0.006 | 90   | 2.39 (1.13–5.05) | 0.022 |
| Ever used sniffed drugs | No  | 1,877 | 1.0 | – | 2,969 | 1.0 | – | 3,392 | 1.0 | – |
|                         | Yes | 71   | 2.75 (1.28–5.87) | 0.009 | 134  | 1.53 (0.74–3.16) | 0.241 | 216  | 1.95 (1.14–3.31) | 0.014 |
| Ever used injected drugs| No  | 1,922 | 1.0 | – | 3,084 | 1.0 | – | 3,577 | 1.0 | – |
|                         | Yes | 9    | – | – | 13 | 1.41 (0.24–8.09) | 0.695 | 21 | 3.55 (1.31–9.61) | 0.013 |
| Previous use of glass syringe | No  | 1,604 | 1.0 | – | 2,627 | 1.0 | – | 2,753 | 1.0 | – |
|                         | Yes | 316  | 0.73 (0.47–1.15) | 0.178 | 444  | 0.78 (0.54–1.12) | 0.186 | 824  | 1.19 (0.89–1.58) | 0.223 |
| Alcohol consumption     | None | 1,368 | 1.0 | – | 1,968 | 1.0 | – | 2,077 | 1.0 | – |
|                         | Light | 472  | 0.87 (0.61–1.25) | 0.455 | 978  | 1.10 (0.74–1.63) | 0.627 | 1,364 | 1.02 (0.77–1.34) | 0.878 |
|                         | Heavy | 141  | 1.66 (0.92–2.98) | 0.093 | 159  | 2.32 (1.31–4.09) | 0.004 | 176  | 1.37 (0.75–2.51) | 0.296 |

CI = confidence interval; OR = odds ratio.

*Weighted ORs adjusted for random effect and age.
have sex with individuals of the same sex share, to some extent, the same risk factors of their partners. The association between the number of sexual partners and the positivity to serologic markers of hepatitis B (and other STDs) is often referred in Brazilian studies carried out either in blood centers\textsuperscript{27,28} or in general population\textsuperscript{29} or, still, in special groups.\textsuperscript{30,31}

These sexual behaviors, found in the north and south regions, were probably related to unsafe sexual practices. The history of STD also expresses these practices. The Brazilian Ministry of Health has conducted several campaigns to promote responsible sexual behavior and has made condoms largely available.\textsuperscript{32} Further efforts could be done to deliver interventions and to conduct in-depth studies to target groups until the age group with high anti-HBV vaccination coverage gets older.

In the southeast, HBV infection was associated with the use of injected drugs; this association is well documented in the literature and in Brazilian studies.\textsuperscript{25,33} In the three regions, the use of non-injecting drugs was also associated with the presence of HBV infection. It is likely that in these settings non-injecting

\begin{table}[h]
\centering
\small
\begin{tabular}{|l|c|c|c|c|}
\hline
\multicolumn{5}{|c|}{Factors associated with hepatitis B infection in three regions of Brazil, 2005} \\
\hline
Characteristics & North & & & South \\
\hline
 & OR (95\% CI)$^*$ & \textit{P} value & OR (95\% CI) & \textit{P} value \\
\hline
Sex & & & & \\
Female & – & – & 1.0 & – & – \\
Male & – & – & 1.49 (1.02–2.19) & 0.041 & – & – \\
\hline
Age (in years) & 1.05 (1.03–1.06) & 0.000 & 1.06 (1.05–1.08) & 0.000 & 1.04 (1.03–1.05) & 0.000 \\
\hline
Read and write & Yes & 1.0 & – & – & – & – \\
No & 3.14 (1.53–6.46) & 0.002 & – & – & – & – \\
\hline
Schooling & Illiterate & – & – & – & 1.0 & – \\
Basic level & – & – & – & – & 0.78 (0.53–1.15) & 0.214 \\
Secondary level and university & – & – & – & – & 0.51 (0.32–0.81) & 0.004 \\
\hline
Paid work past week & Yes & 1.0 & – & – & – & – \\
No & 0.56 (0.40–0.76) & 0.000 & – & – & – & – \\
\hline
Sewage disposal & Public system & – & – & – & – & 1.0 & – \\
Septic tanks & 0.61 (0.40–0.93) & 0.021 & – & – & 1.71 (1.28–2.29) & 0.000 \\
Other destination & 0.83 (0.40–1.72) & 0.617 & – & – & – & – \\
\hline
Blood transfusion & Never & – & – & – & – & 1.0 & – \\
Past 12 months & – & – & – & – & 2.28 (1.11–4.67) & 0.024 \\
Ever & – & – & – & – & 0.68 (0.41–1.15) & 0.152 \\
\hline
Endoscopy & Never & – & – & – & – & 1.0 & – \\
Past 12 months & – & – & – & – & 1.27 (0.80–2.05) & 0.311 \\
Ever & – & – & – & – & 1.33 (0.99–1.80) & 0.059 \\
\hline
Share toothbrush & No & – & – & – & 1.0 & – \\
Yes & – & – & – & – & 1.81 (1.05–3.12) & 0.032 \\
\hline
Condom use & Not started sexual life & – & – & – & – & 1.0 & – \\
Yes, regularly & – & – & – & – & 2.41 (0.96–6.06) & 0.060 \\
Yes, sometimes & – & – & – & – & 5.68 (1.65–8.22) & 0.001 \\
Never & – & – & – & – & 3.90 (1.54–9.88) & 0.004 \\
\hline
Bisexual partner & Not started sexual life & 1.0 & – & – & – & – & – \\
No & 2.37 (0.87–6.42) & 0.089 & – & – & – & – \\
Yes & 1.68 (1.17–2.41) & 0.005 & – & – & – & – \\
\hline
Ever used smoked drugs & No & 1.0 & – & – & – & – & – \\
Yes & 1.58 (1.05–2.36) & 0.026 & – & – & – & – \\
\hline
Ever used inhaled drugs & No & – & – & 1.0 & – & – & – \\
Yes & – & – & 3.85 (1.19–12.4) & 0.024 & – & – \\
\hline
Ever sniffed drugs & No & – & – & – & 1.0 & – & – \\
Yes & – & – & 1.73 (1.01–2.97) & 0.048 & – & – \\
\hline
Ever injecting drugs & No & – & – & – & – & 1.0 & – \\
Yes & – & – & 2.49 (0.82–7.54) & 0.106 & – & – \\
\hline
Classification elitism & Abstemious & – & – & 0.95 (0.63–1.44) & 0.815 & – & – \\
Light weight drinker & – & – & 1.96 (1.06–3.59) & 0.030 & – & – \\
Heavy drinker & – & – & – & – & – & – \\
\hline
\end{tabular}
\caption{Factors associated with hepatitis B infection in three regions of Brazil, 2005}
\label{table:hepatitis_b_factors}
\end{table}

CI = confidence interval; OR = odds ratio.

$^*$ Adjusted ORs corrected for random effect and weighted for age group.
drug users are more prone to other risk behavior, which should be investigated to allow the choice of targeted control measures. The same rationale could be used to explain the association with heavy alcohol consumption in the southeast.

Sharing toothbrush was associated with HBV infection, inexplicably, in the region with higher Human Development Index. The association with history of blood transfusion and gastrointestinal endoscopy in the south should be interpreted with caution. As in Brazil the blood supply is adequately screened for hepatitis B since 1975, it is possible that either the infection occurred before this year or that the exposure to HBV occurred before the transfusion. Endoscopy-related transmission of HBV is rare. Quasi-experimental designs (before and after studies) could be performed to elucidate if blood transfusion and endoscopy still play any role in HBV transmission in southern Brazil.

Schooling was associated with exposure to HBV in the south region. Risk behaviors related to the socioeconomic context could be identified to guide specific interventions. Sewage disposal was associated with HBV infection in the north and south regions, but the association was in opposite directions suggesting that the same situation (household with septic tank) may express different socioeconomic conditions in these two regions. The results for hepatitis C for the whole country showed that there was still room for further control of the infection. As in Brazil the blood supply is adequately screened for hepatitis B since 1975, it is possible that either nonrandom, which may have decreased the magnitude of some of the associations found.

The findings presented herein highlight the diversity of the potential transmission routes for hepatitis B transmission in Brazil. In one hand, it reinforces the importance of national control strategies of large impact already in course such as the immunization of infants, adolescents, and adults up to 49 years of age and blood supply screening. On the other hand, it shows that there is still room for further control measures targeted to different groups within each region.

Received March 18, 2015. Accepted for publication July 7, 2015.

Acknowledgments: We thank University of Pernambuco Foundation for administrative support.

Hepatitis Study Group: Katia Biscuola de Campos, Programa Nacional de Prevenção e Controle das Hepatites Virais/SVS/MSP, Ministerio da Saúde. Cirley Maria de Oliveira Lobato, Serviço de Assistência Especializada, Secretaria Estadual de Saúde, AC. Mônica de Breu Moraes, Secretaria Estadual de Saúde-Acre, Programa Estadual de Hepatites. Janaina Mazarro, LACEN, Rio Branco, Acre. Maria de Nazaré Miranda de Cavalcante, Secretaria de Estado da Saúde do Amapá, Ciôs Omar Sá Miranda, Secretaria de Estado do Saúde do Amapá, Macapá, Amapá, Brazil. Márcia Socorro Cavalcante Porcy, LACEN-Amapá, Brazil. Ana Ruth Silva de Araújo, Universidade Federal do Amazonas. Marilúcia da Silva Garrido, Fundação de Vigilância em Saúde do Amazonas, Departamento de Vigilância Epidemiológica. Márcia Noronha Barbosa, Fundação de Vigilância em Saúde, AM. Raimundo Aldo Tavares, Secretaria Estadual de Saúde Pública, PA. Maria de Fátima Chaves Oliveira, Secretaria Estadual de Saúde, PA. José Américo Lozich de Aquino, LACEN-PA. Juan Miguel Villalobos-Sulcedo, Secretaria Regional de Rondónia, Fábio Luiz Storer, Faculdade de Saúde Pública da Universidade de São Lucas, Porto Velho, RO. Luiz Renerys de Lima Pinheiro, Secretaria de Saúde de Estado do Amapá, Puerto de Cura, PA. Lucimar Bozza, Secretaria Municipal de Saúde de Curitiba. Yatiyo Matsui Moriya, LACEN-Paraná. Esther Buzaglo Dantas-Correa, Universidade Federal de Santa Catarina, Ana Cristina Vidor, Prefeitura Municipal de Florianópolis. Ana Duarte Cardoso, LACEN-SC. Alexandre Alves, Universidade Federal de Ciências da Saúde de Porto Alegre, Maria Eugênia Pinto, Universidade Federal de Ciências da Saúde de Porto Alegre. Zenaida Marion Alves Nunes Lyra Vidal, Instituto de Pesquisa Biológica IPB LACEN RS. Angelica Espinosa Barbosa Miranda, Universidade Federal do Espírito Santo. Moacir Soprani, Secretaria Estadual de Saúde do Espírito Santo. Patrícia Rolim Prates, LACEN-ES. Cristiane Alves Villela-Nogueira, Universidade Federal do Rio de Janeiro. Mariza Miranda Theme-Filha, ENSP-FIOCRUZ. Carlos Augusto da Silva Fernandes, LACEN, RJ. Angela Maria Miranda Spinha, (in memorian), Flair José Carrilho, Departamento de Gastroenterologia da Faculdade de Medicina da USP. Antonio Alci Barone, Departamento de Moléstias Infecciosas e Parasitárias do Hospital das Clínicas da Faculdade de Medicina da USP. Authors’ addresses: Ricardo A. A. Ximenes, Hospital Universitário Oswaldo Cruz, Faculdade de Ciências Médicas de Pernambuco, Universidade de Pernambuco, Pernambuco, Brazil, and Departamento de Medicina Tropical, Universidade Federal de Pernambuco, Universidade Estadual de Pernambuco, Pernambuco, Brazil, E-mail: raaximenes@uol.com.br. Gerusa M. Figueiredo, Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil, E-mail: gfigueiredo@usp.br. Maria Regina A. Cardoso, Departamento de Epidemiologia, Faculdade de Saúde Pública, Universidade de São Paulo, Cerqueira Cesar, São Paulo, Brazil, E-mail: rcardoso@usp.br. Airtón T. Stein and Gabriela Coral, Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, Rio Grande do Sul, Brazil, E-mails: astein@via-rs.net and g.coral@terra.com.br. Regina C. Moreira, Instituto Adolfo Lutz, São Paulo, Brazil, E-mail: regina.morira@gmail.com. Deborah Crespo, Secretaria de Saúde Pública do Pará, Pará, Brazil, E-mail: dcrespo@amazon.com.br. Alex A. dos Santos, Instituto Bioestatístico-IBCT, Pará, Brazil, E-mail: bioestat@yahoool.com.br. Ulisses R. Montarroyos, Instituto de Ciências Biológicas (ICB), Universidade de Pernambuco, Pernambuco, Brazil, E-mail: ulisses_montarroyos@yahoo.com.br. Maria C. C. Brandão, Secretaria de Estado de Saúde, RR, Brazil, E-mail: maria.brandao@seasp.rr.gov.br. Leilane Amaro, Instituto de Medicina Tropical, Universidade Federal do Amazonas, Brazil, E-mail: leilane@idb.gov.br. Leila M. M. B. Pereira, Instituto do Fígado, Universidade Federal do Amazonas, Brazil, E-mail: leilapeireira@pq.cnpq.br. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. WHO Media Centre. Hepatitis B. Fact Sheet No. 204. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html. Accessed November 3, 2014.
2. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS, 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 1329–1339.
3. Ministério da Saúde. 2003. 30 anos do PNU/DEV/EVS/SVS. Brasília, Brazil: Ministério da Saúde.
4. Luna EJA, Veras MASM, Flannery B, Moraes JC, 2009. House-hold survey of hepatitis B vaccine coverage among Brazilian children. Vaccine 27: 5326–5331.
5. Souto FJD, 1999. Distribuição da Hepatite B no Brasil: atualização do mapa epidemiológico e proposições para seu controle. *GED 18*: 143–150.

6. Pereira LMB, Martelli CMT, Merchán-Hamann E, Montarroyos UR, Braga MC, de Lima M, Cardoso MR, Turchi MD, Costa MA, de Alencar IC, Moreira RC, Figueiredo GM, Ximenes RA, Hepatitis Study Group, 2009. Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. *Am J Trop Med Hyg* 81: 240–247.

7. Ximenes RAA, Pereira LMB, Martelli CMT, Merchán-Humann E, Stein AT, Figueiredo GM, Braga MC, Montarroyos UR, Brasil LM, Turchi MD, da Fonseca JC, de Lima MLC, de Alencar LCA, Costa M, Coral G, Moreira RC, Cardoso MRA, 2010. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. *Cad Saúde Publica* 26: 1693–1704.

8. McQuillian GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS, 1999. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. *Am J Public Health* 89: 14–18.

9. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, Chen DS, 2001. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. *Ann Intern Med* 135: 796–800.

10. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS, for the Taiwan Childhood Hepatoma Study Group, 1997. Universal hepatitis B vaccination in Taiwan and incidence of hepatocellular carcinoma in children. *N Engl J Med* 336: 1855–1859.

11. Xia G-L, Liu C-B, Cao H-L, Bi S-L, Zhan M-Y, Su C-A, Nan J-H, Qi X-Q, 1996. Prevalence of hepatitis B and C virus infections in the general population of China. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis B, A, C, D, and E virus infections. *Int Hepatol Commun* 5: 62–73.

12. Liang JH, Wang M, Liu JH, Cai YS, Xu JX, 2010. Study on the immunization coverage and effects of hepatitis B vaccine in the 20–59 years-old population in Guangzhou city [in Portuguese]. *Zhonghua Li Xing Bing Xue Za Zhi* 31: 1336–1339.

13. Al-Falih FZ, Al-Jefri M, Ramia S, Al-Rashed AR, Arif M, Rezig M, Al-Toraif I, Bakhash M, Mislikhkas A, Makki O, Al-Freihir H, Mirdad S, Al-Juma A, Yasin T, Al-Swaleem A, Ayoola A, 1999. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. *J Infect* 38: 167–170.

14. Wasley A, Kruszon-Moran D, Kuhnt W, Ep Simard, Finalli L, McQuillan G, Bell B, 2010. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. *J Infect Dis* 202: 192–201.

15. Wu HX, Andnov A, Giulivi A, Goodchuis NJ, Baptiste B, Fursech J, Poliquin D, Chan JIP, Bolesnikov G, Moffat B, Paton S, Wu J, 2005. Enhanced surveillance for childhood hepatitis B virus infection in China, 1999–2003. *Int J Med Sci* 2: 143–148.

16. Braga WS, Castillo MC, Borges FG, Martinho AC, Rodrigues IS, Azevedo EP, Scauzeca M, Menezes PR, 2012. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the western Brazilian Amazon. *Rev Soc Bras Med Trop* 45: 13–17.

17. Paim J, Travassos C, Almeida C, Bahia L, Maccino J, 2011. The Brazilian health system: history, advances, and challenges. *Lancet* 177: 1778–1791.

18. Ott JJ, Stevens GA, Groeger J, Wiersma ST, 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 30: 2212–2219.

19. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP, 2006. Hepatitis B virus infection: epidemiology and vaccination. *Epidemiol Rev* 28: 112–125.

20. Wasley A, Miller JT, Finelli L, 2007. Surveillance for acute viral hepatitis: United States, 2005. *MMWR Surveill Summ* 56: 1–24.

21. Souto FJ, Fontes CJ, Oliveira JM, Gaspar AM, Lyra LG, 1997. Epidemiological survey of infection with hepatitis B virus in the savannah and wetlands (Fantanal) of central Brazil. *Ann Trop Med Parasitol* 91: 411–416.

22. Silveira TR, da Fonseca JC, Rivera L, Fay OH, Tapia R, Santos JS, Urdeneta E, Clemens SAC, 1999. Hepatitis B seroprevalence in Latin America. *Rev Panam Salud Publica* 6: 378–383.

23. EL Khouri M, Duarte LS, Ribeiro RE, da Silva LFF, Camargo LMA, dos Santos VA, Burattini MN, Corbett CE, 2005. Seroprevalence of hepatitis B virus and hepatitis C virus in Monte Negro in the Brazilian western Amazon region. *Clinics* 60: 29–36.

24. Diel R, Helle J, Gottschalk R, 2005. Transmission of hepatitis B in Hamburg, Germany, 1998–2002: a prospective, population-based study. *Med Microbiol Immunol (Berl)* 194: 193–199.

25. Oliveira MLA, Bastos FI, Telles PR, Yoshida CFT, Schatzmayer HG, Paetzold U, Pauli G, Schreier E, 1999. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. *Braz J Med Biol Res* 32: 1107–1114.

26. de Souza MG, Passos ADC, Machado AA, Figueiredo JC, Ercolino AP, 2004. HIV and hepatitis B virus coinfection: prevalence and risk factors [in Portuguese]. *Rev Soc Bras Med Trop* 37: 391–395.

27. Patavino GM, Almeida-Neto C, Liu J, Wright DJ, Mendrone-Junior A, Ferreira MI, Busch MP, Sabino EC, NHLBI Retrosurvey Epidemiology Study-II (REDS-II), International Component, 2012. Number of recent sexual partners among blood donors in Brazil: associations with donor demographics, donation characteristics, and infectious disease markers. *Transfusion* 52: 151–159.

28. Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S, 2008. Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. *J Med Virol* 80(5): 53–57.

29. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and hepatitis C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.

30. Pereira RARA, Mussi ADH, Azevedo VCS, Souto FJ, 2006. Risk factors for HBV, HCV and HDV infections among drug users in the central-west region of Brazil. *Rev Soc Bras Med Trop* 39: 151–159.

31. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.

32. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.

33. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.

34. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.

35. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.

36. Miranda AE, Figueiredo NC, Schmidt R, Page-Shafer KA, 2008. Population-based survey of the prevalence of HIV, syphilis, hepatitis B and C infections, and associated risk factors among young women in Vitória, Brazil. *AIDS Behav* 12: 796–800.